Submission & ApprovalLast reviewed April 2026

New Drug Application(NDA)

A formal request to the FDA for approval to market a new pharmaceutical drug in the United States.

Usage Examples

The company submitted an NDA for their novel diabetes treatment.
FDA accepted the NDA for filing and assigned a PDUFA date.
The NDA included data from three pivotal Phase 3 clinical trials.

What is NDA?

A New Drug Application (NDA) is the formal submission a pharmaceutical company makes to the FDA to request approval to market a new drug. The NDA contains all scientific data demonstrating the drug's safety and effectiveness for its proposed use.

The NDA must include complete reports of preclinical and clinical studies, information about the drug's composition and manufacturing, proposed labeling, and patent information. The FDA review process typically takes 10-12 months for standard reviews and 6 months for priority reviews.

NDAs are submitted under Section 505(b)(1) of the Federal Food, Drug, and Cosmetic Act for drugs with full reports of safety and effectiveness investigations.

Regulatory Context

This term appears most often in submission & approval workflows where submission quality, regulatory evidence, and audit readiness depend on consistent language. It is commonly referenced alongside 21 CFR 314, 21 CFR 312.

FDAICHEMA

When This Matters

The company submitted an NDA for their novel diabetes treatment.
FDA accepted the NDA for filing and assigned a PDUFA date.
The NDA included data from three pivotal Phase 3 clinical trials.

Common Mistakes

Treating submission readiness as a formatting-only check without lifecycle validation.
Using outdated guidance references across modules and summaries.
Missing cross-functional review between RA, CMC, and quality before submission.

Related Regulations

21 CFR 31421 CFR 312

How to File an NDA with FDA

Submit a New Drug Application to obtain FDA approval to market a drug in the United States.

1
Complete Phase 3 pivotal trials
Finalize clinical efficacy and safety evidence meeting FDA expectations for the indication — typically two adequate and well-controlled pivotal trials, or one plus confirmatory evidence for certain pathways.
2
Hold pre-NDA meeting
Request a Pre-NDA (Type B) meeting 6-12 months before planned filing. Align with FDA on dataset structure, planned integrated summaries, CMC readiness, and open scientific questions.
3
Prepare the eCTD submission
Assemble Module 1 (regional administrative), Module 2 (summaries: QOS, nonclinical overview, clinical overview/summary), Module 3 (CMC), Module 4 (nonclinical reports), Module 5 (clinical reports). Include Pediatric Study Plan and Risk Management Plan.
4
Submit via eCTD + ESG
Transmit the NDA through FDA ESG in eCTD v4.0.0 format. Pay the PDUFA user fee concurrently. Receive ESG acknowledgments confirming gateway acceptance.
5
Pass 60-day filing review
FDA conducts filing review over 60 calendar days. Responds with "filing over protest", "filed", or "Refuse to File" (RTF). RTF requires remediation and resubmission.
6
Support substantive review
Respond to Information Requests during 10-month standard review (6-month priority review). Manage midcycle and late-cycle meetings. Support facility inspections (PAI) and BIMO inspections of pivotal trial sites.
7
Prepare for Advisory Committee (if convened)
If FDA convenes an AdCom, prepare briefing materials, presentation, and panel Q&A readiness. AdCom recommendations are advisory but influential.
8
Receive action letter at PDUFA date
FDA issues Approval Letter, Approvable Letter, or Complete Response Letter at the PDUFA action date. CRL requires response and new 2-6 month review cycle.

Frequently Asked Questions

An NDA is for new drugs requiring full safety and efficacy data, while an ANDA (Abbreviated NDA) is for generic drugs that reference an approved drug and only need to demonstrate bioequivalence.

Standard NDA reviews have a 10-month goal date, while priority reviews have a 6-month goal date under PDUFA timelines.

A 505(b)(2) NDA allows applicants to rely partly on FDA findings for a previously approved drug, reducing the need for original clinical data while still enabling approval of modified versions.